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BRIEF DEFINITIVE REPORT

Bromodomain protein BRD4 directs and sustains
CD8 T cell differentiation during infection

In response to infection, pathogen-specific CD8 T cells differentiate into functionally diverse effector and memory T cell
populations critical for resolving disease and providing durable immunity. Through small-molecule inhibition, RNAi studies, and
induced genetic deletion, we reveal an essential role for the chromatin modifier and BET family member BRD4 in supporting
the differentiation and maintenance of terminally fated effector CD8 T cells during infection. BRD4 bound diverse regulatory
regions critical to effector T cell differentiation and controlled transcriptional activity of terminal effector–specific superenhancers in vivo. Consequentially, induced deletion of Brd4 or small molecule–mediated BET inhibition impaired
maintenance of a terminal effector T cell phenotype. BRD4 was also required for terminal differentiation of CD8 T cells in the
tumor microenvironment in murine models, which we show has implications for immunotherapies. Taken together, these data
reveal an unappreciated requirement for BRD4 in coordinating activity of cis regulatory elements to control CD8 T cell fate
and lineage stability.

Introduction
CD8 T cells are critical mediators of host defense against intracellular pathogens and malignancy (Chang et al., 2014). Upon
recognition of cognate antigen, CD8 T cells become activated,
rapidly expand, and differentiate into effector cells critical for
resolution of disease. Following pathogen clearance, a relatively
small population of antigen-specific effector cells persists and
gives rise to memory T cells. It is apparent that the CD8 T cell
response to infection is accompanied by extensive functional
heterogeneity at both the effector and memory phases (Jameson
and Masopust, 2018). Understanding the molecular signals
controlling T cell differentiation provides insight for harnessing
discrete T cell states for therapeutic strategies.
Differential expression levels of KLRG1 and CD127 delineate
effector populations with distinct fates during acute infections
(Chang et al., 2014; Joshi et al., 2007; Kaech et al., 2003). Nascent
cytotoxic effector CD8 T cells rapidly lose expression of
CD127—expressed by naive cells—and form a transitional population of CD127loKLRG1lo early effector cells (EECs) before

upregulation of KLRG1 or CD127 (Diao and Pipkin, 2019). KLRG1
expression correlates with terminal differentiation, and CD127
marks cells with a greater degree of memory potential (Chang
et al., 2014; Joshi et al., 2007). As such, KLRG1loCD127hi cells are
referred to as memory precursor T cells (MP cells) and
KLRG1hiCD127lo cells as terminal effector T cells (TE cells). MP
cells display enhanced multipotency compared with TE cells and
more efficiently give rise to central memory T cells (TCM cells),
effector memory T cells (TEM cells), and tissue-resident memory
T cells (TRM cells; Kaech et al., 2003; Mackay et al., 2013; Milner
and Goldrath, 2018); however, select TE cells are able to persist
for several months after infection, forming a terminally differentiated TEM cell population (t-TEM cells) or long-lived effector
population (Kurd et al., 2020; Milner et al., 2020a; Milner et al.,
2020b; Olson et al., 2013). Canonical transcription factors known
to regulate antiviral T cell differentiation include Id3 (Ji et al.,
2011; Yang et al., 2011), TCF1 (Zhou et al., 2010), Bcl6 (Ichii et al.,
2002; Liu et al., 2019), STAT3 (Cui et al., 2011), and Foxo1 (Kim
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Results and discussion
In vivo loss-of-function screen reveals chromatin modifier
BRD4 as a critical regulator of CD8 T cell differentiation during
infection
Chromatin modifiers and transcription factors can differentially
regulate the formation of divergent cell states without varying
expression levels, often limiting our ability to predict how key
Milner et al.
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regulators of gene expression control T cell lineage specification
(Milner et al., 2017; Yu et al., 2017). We have previously used a
pooled in vivo RNAi screening strategy (Chen et al., 2014) to
identify functional regulators of TRM cell formation (Milner
et al., 2017). Using a similar microRNA-based shRNA (shRNAmir) library and approach (Chen et al., 2014; Milner et al., 2017),
we screened 215 shRNAmirs to identify functional regulators of
early memory T cell differentiation during lymphocytic choriomeningitis virus (LCMV) infection (Fig. 1 A and Fig. S1 A).
Several transcription factors known to be important for longlived memory or TCM cells were confirmed in this screening
approach, including Id3 (Ji et al., 2011; Yang et al., 2011), Klf2 (Bai
et al., 2007; Hart et al., 2012; Preston et al., 2013), and Bcl6 (Ichii
et al., 2002; Liu et al., 2019), whereas Id2 (Cannarile et al., 2006;
Knell et al., 2013; Masson et al., 2013) and Runx3 (Wang et al.,
2018) were required for formation of CD62Llo t-TEM/TEM cells
relative to TCM cells (Fig. 1 A and Table S1). A notable hit from
this loss-of-function screen included chromatin modifier BRD4.
Brd4 shRNAmirs were enriched in the CD62Lhi population relative to CD62Llo cells, identifying BRD4 as a putative mediator of
t-TEM/TEM cell differentiation. BRD4 has emerged as a key regulator of cellular differentiation in multiple contexts, including
diverse cancer types (Donati et al., 2018; Filippakopoulos et al.,
2010; Ren et al., 2018), hematopoietic stem cells (Dey et al.,
2019), CD4 T cell populations (Bandukwala et al., 2012; Cheung
et al., 2017a; Cheung et al., 2017b; Mele et al., 2013), and CD8
T cells in vitro (Chee et al., 2020; Georgiev et al., 2019; Kagoya
et al., 2016), but the role of BRD4 in regulating T cell differentiation in vivo and in the context of infection remains unclear.
BRD4 is a member of the BET protein family, functioning in
many cases as a chromatin reader that binds acetylated lysine
residues in enhancer regions and establishes a molecular scaffold for controlled transcription of critical genes (Dey et al., 2019;
Lee et al., 2017; Lovén et al., 2013). We first sought to validate
BRD4 as a putative positive regulator of TE cell and/or early
t-TEM cell formation as observed in the in vivo screen. Two
distinct Brd4 shRNAmirs mediated 70%–80% knockdown efficiency, confirming their on-target activity (Fig. S1 B). Congenically distinct CD8 T cells expressing a transgenic TCR
recognizing the LCMV GP33-41 epitope presented by MHCI (P14
cells) were transduced with a control retrovirus—encoding Cd19
shRNAmir—or a Brd4 shRNAmir encoding retrovirus and
transferred into recipient mice subsequently infected with
LCMV. Consistent with the loss-of-function screen results, we
found that Brd4 RNAi impaired the formation of CD127loCD62Llo
t-TEM cells, resulting in a greater frequency of TCM cells (Fig. 1 B).
We also assessed how depletion of BRD4 impacted CD8 T cell
differentiation over the course of LCMV infection and detected a
reduced frequency of KLRG1hi P14 cells at all time points, as well
as an increased frequency of CD127loKLRG1lo EECs on day 5 of
infection (Fig. 1 C). CX3CR1 expression levels on CD8 T cells are
reflective of the degree of terminal differentiation (Böttcher
et al., 2015; Gerlach et al., 2016; Milner et al., 2020a), and
knockdown of Brd4 resulted in a reduced frequency of CX3CR1hi
P14 cells (Fig. 1 D). Taken together, informed through a pooled
in vivo screening approach, we identified an essential role for
BRD4 in the formation of TE cells as well as the more terminally
Journal of Experimental Medicine
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et al., 2013; Hess Michelini et al., 2013; Utzschneider et al., 2018)
as critical regulators of MP/TCM cells, and Id2 (Cannarile et al.,
2006; Knell et al., 2013; Masson et al., 2013), Zeb2 (Dominguez
et al., 2015; Omilusik et al., 2015; Omilusik et al., 2018), Blimp1
(Kallies et al., 2009; Rutishauser et al., 2009), STAT4 (Mollo
et al., 2014), and T-bet (Joshi et al., 2007) are required for
more terminally differentiated populations.
Analogous to infection responses, tumor-infiltrating CD8 T
lymphocytes (TILs) also exist in a range of cell states, wherein
multipotent progenitor exhausted cells can be distinguished as
PD-1Int/hiSlamf6hiTim3lo and express elevated levels of the
transcription factors TCF1 and Id3 compared with terminally
exhausted cells that are PD-1hiTim3hi and Id3loTCF1lo (Im et al.,
2016; Miller et al., 2019; Milner et al., 2020b; Siddiqui et al.,
2019). Progenitor exhausted cells provide sustained antitumor
immunity and are more responsive to immunotherapies, such as
checkpoint blockade and therapeutic vaccines (Im et al., 2016;
Miller et al., 2019; Siddiqui et al., 2019); therefore, understanding the signals promoting and enforcing CD8 T cell differentiation is relevant for cancer immunotherapies.
Here, we sought to identify transcriptional and epigenetic
signals regulating CD8 T cell differentiation over the course of
infection. We employed a targeted in vivo RNAi loss-of-function
screen to identify transcription factors and epigenetic regulators
controlling the differentiation of CD8 T cells during acute viral
infection. The pooled screening approach identified an essential
role for the chromatin modifier bromodomain-containing protein 4 (BRD4) in regulating T cell fate specification, and through
multiple distinct approaches, we show that BRD4 is required for
both promoting and sustaining a terminally differentiated CD8
T cell state. Through genome-wide binding analysis, we found
that BRD4 binds near genes critical to CD8 T cell differentiation
and effector subset identity. Remarkably, >99% of TE cell superenhancers were occupied by BRD4 in vivo, and consequentially,
induced deletion of Brd4 resulted in loss of super-enhancer
transcriptional activity and impaired maintenance of a TE
phenotype. Last, we extended our findings to the tumor microenvironment, where we demonstrated that BRD4 supports
formation of terminally differentiated CD8 T cells in tumors, and
therapeutic targeting of BRD4 in CD8 T cells can modify immunotherapy efficacy. Taken together, we define an essential
role for BRD4 in linking cis regulatory elements to CD8 T cell
differentiation and function. Understanding how effector and
memory CD8 T cell subset differentiation can be manipulated
in vivo, such as targeting of bromodomain-containing proteins
with small-molecule inhibitors, holds promise for vaccination or
immunotherapy approaches designed for controlling infection
and malignancy.

2 of 15

fated memory population (i.e., CD127loCD62Llo) t-TEM cells. Additionally, we previously detected BRD4 as a top candidate in a
TRM cell differentiation screen (Milner et al., 2017), and consistent with these findings, Brd4 RNAi impaired the early formation of CD69hiCD103hi cells in the intestinal epithelium (Fig.
S1 C).
We next generated mixed bone marrow chimeric mice
comprised of a 1:1 mixture of congenically distinct
Brd4fl/flErt2Cre/+ bone marrow and Brd4+/+ bone marrow to further evaluate a CD8 T cell–intrinsic role for BRD4 and validate
Milner et al.
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shRNAmir knockdown studies (Fig. 1 E). Reconstituted chimeric
mice were infected with LCMV and tamoxifen was administered
on days 5–7 of infection to induce Cre-mediated deletion of Brd4.
Induced depletion of BRD4 on days 5–7 of infection did not impact the overall number of tetramer+ Brd4fl/flErt2Cre/+ cells as the
mean ratio of BRD4-deficient, and control cells remained at a
similar 1:1 ratio on day 8 of infection (Fig. 1 E and Fig. S1 D);
however, deletion of Brd4 resulted in a reduction in the frequency of antigen-specific, terminally fated KLRG1hiCD127lo TE
cells and a greater proportion of KLRG1loCD127hi MP cells
Journal of Experimental Medicine
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Figure 1. In vivo RNAi screen reveals BRD4 as a critical regulator of CD8 T cell differentiation during infection. (A) Relative enrichment of shRNAmirs in
splenic CD62Lhi and CD62Llo cells from an in vivo RNAi screen, reported as the average Z-score from three independent screens where each independent
screen was performed by pooling DNA from sorted P14 populations from 15–18 mice. (B–D) Congenically distinct P14 cells were transduced with Brd4
shRNA–encoding or control shRNA–encoding retroviruses and transferred into recipient mice subsequently infected with LCMV. Frequency of TCM, TEM, t-TEM
memory T cell populations (B), frequency of CD127loKLRG1hi expressing cells (C), or frequency of CX3CR1hi cells in response to LCMV infection (D). (E) Bone
marrow chimera mice were generated by adoptive transfer of 1:1 mixed bone marrow cells from CD45.1 Brd4+/+ control mice (Ctrl) and CD45.2 Brd4fl/flErt2Cre/+
mice (inducible Brd4 [iBrd4]) into irradiated mice (left). Reconstituted mice were infected with LCMV and treated with tamoxifen on days 5–7 of infection to
induce deletion of Brd4. Representative flow cytometry plots (left) and quantification (right) of the ratio of Brd4fl/flErt2Cre/+ CD8 T cells and control cells before
infection and 8 d after infection. (F and G) Frequency of CD127 and KLRG1 (F) or CX3CR1 and KLRG1 expressing tetramer+ cells from E (G). (H) Representative
flow cytometry plots indicating the ratio of Brd4fl/flErt2Cre/+ and control tetramer+ CD8 T cells (left, similar to E) and the ratio of Brd4fl/flErt2Cre/+ and control cells
among all tetramer+ KLRG1hiCX3CR1hi and KLRG1loCX3CR1lo CD8 T cell populations (right). Graphs show mean ± SEM of n = 7–10 mice pooled from two or three
independent experiments (B and C); n = 4 from one representative of two independent experiments at days 5 or 7 of infection (D); n = 15 pooled from three
independent experiments (E and F) or n = 11 pooled from two independent experiments (G and H). *, P < 0.05; ***, P < 0.005. Symbols represent an individual
mouse (B–H).
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In vivo BET inhibition impairs CD8 T cell differentiation during
viral infection
BET proteins bear characteristic tandem bromodomains (BDs;
BD1 and BD2) that bind acetylated lysine residues facilitating
protein–protein interactions (Shi and Vakoc, 2014). Widely used
BET inhibitors JQ1 and OTX-015 potently impair the activity of
BET proteins, especially BRD4, through competitively binding
bromodomains (Boi et al., 2015; Filippakopoulos et al., 2010).
Additionally, the small molecule MS402 selectively targets BD1
of BRD4, preferentially inhibiting BRD4-induced expression of
genes key to lineage specification (Cheung et al., 2017a). BET
protein inhibitors represent promising therapeutic modalities
for a number of disease states ranging from cancer to autoimmunity. In vitro treatment with BET inhibitors has been shown
to modulate T cell activation (Chee et al., 2020; Georgiev et al.,
2019; Kagoya et al., 2016); however, the in vivo effects of BET
inhibition and small-molecule targeting of BRD4 in CD8 T cell
differentiation during infection is not known.
Given the striking impact of BRD4 deficiency on TE cell differentiation, we tested if this phenotype could be recapitulated
through BET inhibition in vivo. P14 cells were adoptively
transferred to recipient mice subsequently infected with LCMV
and treated with JQ1, MS402, OTX-O15, or corresponding vehicle
controls from days 1–4 of infection (Fig. 2 A). On day 5 of infection, we assessed the phenotype of donor P14 cells and found
that all BET inhibitors impaired the early formation of KLRG1hi
TE cells, resulting in a greater proportion of KLRG1lo EECs (Fig. 2
A), consistent with RNAi and genetic deletion studies. Failure to
optimally generate KLRG1hi cells was also reflected by reduced
frequencies of CX3CR1hi, CD43lo, and CD27lo cells, but an elevated frequency of CD62Lhi cells (Fig. 2 B). Additionally, JQ1
treatment impaired the early formation of intestinal
CD69hiCD103hi TRM cells (Fig. S1 G), consistent with RNAi studies
(Fig. S1 C). As there are four members of the BET protein family
(BRDT, BRD2, BRD3, and BRD4), it was unclear what degree the
observed phenotype of BET inhibition was solely due to BRD4
inhibition. Only robust expression of Brd2 and Brd4 was detected
in CD8 T cell populations during LCMV infection (Fig. S2 A),
with minimal variation in expression between CD8 T cell subsets. To clarify the effect of BET inhibitors on CD8 T cell fate, we
evaluated a regulatory role for BRD2 using two distinct Brd2
Milner et al.
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shRNAmirs that result in ∼60% to 70% Brd2 knockdown efficiency (Fig. S2 B). Brd2 RNAi resulted in a subtle loss of KLRG1hi
cells on day 5 (Fig. 2 C) and day 7 of infection (Fig. S2 C);
therefore, we concluded that, while both Brd2 and Brd4 regulated
aspects of CD8 T cell differentiation, loss of BRD4 activity likely
conferred the strongest BET-mediated contribution to impaired
differentiation of TE cells during LCMV infection. Furthermore,
BET proteins are broadly expressed in a wide range of cell types,
and thus, indirect effects of BET inhibition on other cell types
may also contribute to the observed phenotype in virus-specific
CD8 T cells.
To further evaluate the degree to which BET inhibition impairs BRD4 activity in CD8 T cells in vivo, we profiled the
transcriptome of KLRG1loCD127lo EEC P14 cells from JQ1- or
vehicle-treated mice as well as shBrd4 or shCtrl P14 cells in a
mixed transfer setting (Fig. 2 D). Splenic KLRG1loCD127lo EECs
were sorted for RNA sequencing analyses rather than bulk P14
cells to avoid confounding transcriptional changes caused by
differing frequencies of TE cells, as well as to further understand
the perceived impairment in the transition from an EEC state to
a TE state in BRD4 knockdown cells (Fig. 1 C and Fig. 2 A). We
found that 89% of the transcripts downregulated by Brd4 RNAi
were also suppressed by in vivo JQ1 treatment, and nearly 80%
of transcripts upregulated by Brd4 RNAi were similarly upregulated by JQ1 treatment (Fig. 2 D). Gene set enrichment analysis
(Fig. 2 D) further confirmed that JQ1-mediated BET inhibition
and Brd4 knockdown exerted similar transcriptional changes in
KLRG1lo EEC P14 cells at early times after LCMV infection. Validation of key differentially expressed genes revealed elevated
TCF1 (encoded by Tcf7) and Eomes, reduced GzB production, but
similar expression of T-bet, consistent with mRNA levels for
these targets (Fig. 2, E and F). These data suggest that BET inhibition might represent a therapeutic opportunity for targeting
BRD4 activity and modulating CD8 T cell differentiation in vivo.
BRD4 binds fate-specifying genes to coordinate effector CD8
T cell differentiation
Early inhibition of BRD4 activity with JQ1 or depletion of BRD4
through shRNAmir approaches limited the differentiation of
terminally fated effector CD8 T cells, resulting in a greater frequency of the more multipotent EEC population (Fig. 2). Furthermore, induced Brd4 deletion resulted in a reduced
abundance of terminally differentiated cells and enhanced accumulation of memory-like KLRG1loCX3CR1lo tetramer+ cells
(Fig. 1 H). These findings indicate that BRD4 is important for TE
cell differentiation and may facilitate maintenance of the TE cell
population. To further address this, we profiled the transcriptome of TE, EEC, and MP tetramer+ cells following induced
deletion of Brd4 on days 5–7 of LCMV infection sorted from
mixed bone marrow chimera mice (Fig. 3 A). Loss of Brd4 dramatically changed the gene-expression program in all three effector populations. Principle component analysis revealed that
Brd4-deficient populations were transcriptionally distinct from
control populations (Fig. 3 A); however, comparison of expression levels of TE-, EEC-, and MP-signature gene sets between
control versus mutant subsets revealed that BRD4 was required
for expression of lineage-specific genes in each cell type, as TE,
Journal of Experimental Medicine
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(Fig. 1 F). Loss of BRD4 also resulted in a dramatically reduced
frequency of KLRG1hiCX3CR1hi cells and a greater frequency of
KLRG1loCX3CR1lo cells (Fig. 1 G). Despite no change in the overall
mean ratio of total WT control and mutant GP33-41–specific cells
on day 8 of infection (Fig. 1 E), we detected a greater abundance
of KLRG1loCX3CR1lo cells with loss of BRD4 and a decreased
overall abundance of KLRG1hiCX3CR1hi cells (Fig. 1 H). Further
highlighting the critical and dynamic role of BRD4 in CD8 T cell
immunity, we found that deletion of Brd4 at early infection time
points—days 1–5 of infection—not only impacts cellular differentiation (as in Fig. 1 F) but also affects the overall accumulation
of antigen-specific CD8 T cells (Fig. S1, E and F). Therefore, BRD4
is a critical mediator of CD8 T cell differentiation during acute
viral infection and is required for optimal formation of a terminally differentiated cell state.
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EEC, and MP signature transcripts were predominantly downregulated in each BRD4-deficient subset compared with the
corresponding WT subset (Fig. 3 B). This finding was further
exemplified through volcano plots (Fig. 3 C, top) and gene set
enrichment analyses (Fig. 3 C, bottom), wherein BRD4-deficient
effector T cells failed to upregulate 62%–82% of the lineageMilner et al.
BRD4 regulates CD8 T cell differentiation

Downloaded from http://rupress.org/jem/article-pdf/218/8/e20202512/1416427/jem_20202512.pdf by Washington University In St. Louis Libraries user on 13 June 2021

Figure 2. In vivo BET inhibition impairs CD8 T cell differentiation during infection. P14 CD8 T cells were transferred into congenically distinct recipient
mice subsequently infected with LCMV. (A) Infected mice were treated with 50 mg/kg JQ1, 10 mg/kg JQ1, 40 mg/kg MS402, 50 mg/kg OTX-O15, or corresponding vehicle controls. Frequency of splenic KLRG1hi and KLRG1lo cells on day 5 of infection. (B) Frequency of CD62Lhi, CX3CR1hi, and CD43loCD27lo cells
following daily 50 mg/kg JQ1 or vehicle treatments on day 7 of infection. (C) Congenically distinct P14 cells were transduced with Brd2 shRNA– or control
shRNA–encoding retroviruses and transferred into recipient mice subsequently infected with LCMV. Representative flow cytometry plots (right) indicate the
frequency of KLRG1hiCD127lo-expressing cells on day 5 of infection. (D) On day 5 of infection, CD127loKLRG1lo EECs were sorted for RNA sequencing analysis
following the experimental schematic outlined in A or in a mixed transfer setting for each shRNAmir targeting Brd4. Expression of genes co-downregulated
(blue, ≥1.3-fold) or co-upregulated (green, ≤1.3-fold) in BRD4-deficient cells (top) was evaluated in P14 cells sorted from JQ1 or vehicle-treated mice (middle)
and corresponding gene set enrichment analyses were performed (bottom). (E) Frequency of TCF1hi or GzBhi P14 cells following daily 50 mg/kg JQ1 or vehicle
treatments on day 7 of infection. (F) T-box transcription factor expression in P14 cells following daily 50 mg/kg JQ1 or vehicle treatments on day 7 of infection.
Graphs show mean ± SEM of n = 9 mice pooled from three independent experiments (A, top); n = 7 pooled from two independent experiments (A, middle); n = 4
from one representative of two independent experiments at days 5 or 7 of infection (A, bottom); n = 4–5 from one representative of two independent experiments on day 7 of infection (B, E, and F); and n = 4 from one representative of two independent experiments on day 5 of infection (C). RNA sequencing was
performed in duplicate, wherein each replicate consisted of KLRG1loCD127lo sorted P14 cells pooled from two mice on day 5 of LCMV infection. *, P < 0.05; **,
P < 0.01; ***, P < 0.005. NES, normalized enrichment score; FDR, false discovery rate q value. Symbols represent an individual mouse (A–C, E, and F).

specific gene program. Notably, BRD4-deficient TE cells were
enriched for MP and EEC gene expression signatures relative to
control TE cells, demonstrating that induced loss of BRD4 resulted in enhanced expression of genes associated with less
terminally fated T cell states (Fig. 3 D). Taken together, these
data indicate that BRD4 was critical for promoting and/or
Journal of Experimental Medicine
https://doi.org/10.1084/jem.20202512
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maintaining the identity of each of the specialized effector CD8
T cell populations (i.e., TE, EEC, and MP) during acute infection,
especially TE cells (Fig. 3, C and D).
In diverse cell types, BET proteins coordinate expression of
fate-determining molecules primarily through recruitment of
transcriptional and chromatin-modifying complexes to regulatory enhancer regions (Cochran et al., 2019; Shi and Vakoc,
Milner et al.
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Figure 3. BRD4 binds fate-specifying genes to coordinate effector CD8 T cell differentiation. (A) Reconstituted mixed bone marrow chimera mice were
infected with LCMV and treated with tamoxifen on days 5–7 of infection. On day 8 of infection, tetramer+ CD127hiKLRG1lo MP, CD127loKLRG1lo EEC, and
CD127loKLRG1hi TE cells were sorted for RNA sequencing analysis, and principal component analysis of transcriptomic data was performed (bottom). RNA
sequencing analysis was performed in triplicate, wherein each sample was composed of cells pooled from two mice. (B) Gene expression profile of TE, EEC, and
MP signature gene sets in sorted Brd4+/+ WT and Brd4−/− KO populations from experimental setup in A. (C) Volcano plots (top) and gene set enrichment
analyses (bottom) of signature TE, EEC, and MP gene sets between Brd4+/+ WT and Brd4−/− KO populations from A. (D) Volcano plots (top) and gene set
enrichment analyses (bottom) of signature EEC and MP gene sets between Brd4+/+ WT TE and Brd4−/− KO TE populations. (E) Distribution of genome-wide
BRD4 binding in TE P14 cells sorted on day 8 of LCMV infection. ChIP-seq analysis was performed in duplicate, wherein each sample was composed of cells
pooled from five mice. (F) Expression profile of genes relevant to CD8 T cell differentiation, migration, and function in WT and KO TE cells occupied by BRD4 in
TE cells in vivo. (G) Representative BRD4 and H3K27ac peaks near Id2 and Cx3cr1 loci in TE cells with reproducible peaks highlighted (gray) using the ENCODE
ChIP-seq pipeline. (H) Following LCMV infection, mice were treated with 50 mg/kg JQ1 or vehicle on days 5–7 of infection, and tetramer+ cells were sorted for
RNA sequencing analysis, and subsequent principal component analysis (middle) or gene set enrichment analysis with TE signature genes (right) was performed. Samples were sorted in duplicate, wherein each sample was combined from two mice. (I) Donor P14 cells were phenotyped for CX3CR1 and KLRG1
expression levels on day 8 of LCMV infection following JQ1 or vehicle treatment on days 5–7. Graphs show mean ± SEM of n = 4 mice from one representative
of two independent experiments (I). ***, P < 0.005. NES, normalized enrichment score; FDR, false discovery rate q value; TSS, transcription start site; TTS,
transcription termination site; UTR, untranslated region. Symbols represent an individual mouse (I).

2014). Given that induced deletion of Brd4 resulted in an impairment in TE cell formation as well as a loss of TE cell transcriptional identity, we speculated that BRD4 binds to and
promotes expression of key genes essential to effector T cell
differentiation and the TE lineage. Genome-wide BRD4 binding
was profiled in splenic P14 TE cells on day 8 of LCMV infection
using chromatin immunoprecipitation sequencing (ChIP-seq).
Journal of Experimental Medicine
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Figure 4. BRD4 enforces effector identity and regulates transcriptional activity of TE super-enhancers. (A) Reconstituted mixed bone marrow chimeric
mice were infected with LCMV and subsequently treated with tamoxifen daily on days 8–12 of infection (left). Frequency of tetramer+ Brd4−/− KO and Brd4+/+
Milner et al.
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We detected BRD4 enrichment in gene bodies (comprising only
∼1% to 2% of the genome), with 75.8% of BRD4 peaks located in
promoter/transcription start sites, introns, untranslated regions, and transcription termination sites (Fig. 3 E). Examination of key loci bound by BRD4 revealed numerous molecules
critical to effector CD8 T cell fate, function, and localization, and
many of these relevant BRD4 targets exhibited failed upregulation with BRD4 deficiency (Fig. 3 F). Notable BRD4-sensitive
targets included Id2, a transcriptional regulator essential for
TE cell formation, and chemokine receptor Cx3cr1, which is
markedly upregulated in TE cells (Fig. 3 F; Böttcher et al., 2015;
Cannarile et al., 2006; Gerlach et al., 2016; Omilusik et al., 2018).
BRD4 binding was observed at the Id2 and Cx3cr1 loci, including
near promoter regions (Fig. 3 G). As a key function of BRD4 in
other cell types is binding to enhancer regions to promote gene
expression (Dey et al., 2019; Lee et al., 2017; Lovén et al., 2013),
BRD4 binding patterns were contextualized with H3K27ac
marks in TE cells (Yu et al., 2017). Indeed, we identified extensive overlap between BRD4 peaks and H3K27ac peaks (Fig. 3 G);
however, the abundance of BRD4 at gene bodies suggests that an
additional key role of BRD4 in CD8 T cells is direct transcription
of genes in addition to regulating transcriptional activity of
enhancers. Certain genes were upregulated with loss of Brd4,
and this could be attributed to failed upregulation of transcriptional repressors or alternative functions of BRD4 acting to repress select gene targets. In complementary experiments, later
chemical inhibition of BRD4 on days 5–7 of infection also dramatically modified the gene expression program in TE, EEC, and
MP cell populations compared with cells sorted from vehicletreated mice (Fig. 3 H). TE cells sorted from mice treated with
JQ1 exhibited impaired expression of characteristic TE cell
transcripts, as determined through gene set enrichment analysis
(Fig. 3 H), and resulted in rapid alterations in the phenotype of
antigen-specific CD8 T cells (Fig. 3 I). Taken together, BRD4
binds to and promotes expression of genes central to CD8 T cell
differentiation.
BRD4 enforces effector identity and regulates activity of TE
super-enhancers
The robust occupancy of BRD4 at critical loci and the reduced
expression of key TE cell–specific transcripts in BRD4-deficient
cells foreshadowed an essential role for BRD4 in sequentially
maintaining TE cell identity in addition to regulating differentiation. We sought to further clarify the role of BRD4 in
Milner et al.
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supporting the maintenance of terminally differentiated effector
cells following the peak of infection, after which the TE cell
population is relatively stable (Chang et al., 2014). We induced
Brd4 deletion in mixed bone marrow chimeric mice through
tamoxifen administration on days 8–12 of infection (Fig. 4 A).
Consistent with tamoxifen treatment on days 5–7 of infection,
we detected no change in the overall accumulation of Brd4−/−
tetramer+ cells on day 14 or later infection time points (Fig. 4 A);
however, despite no change in the accumulation of antigenspecific CD8 cells, induced deletion of Brd4 resulted in a profound loss in the frequency of CD127loKLRG1hi and
KLRG1hiCX3CR1hi cells and a greater frequency of
CD127hiKLRG1lo and KLRG1loCX3CR1lo cells (Fig. 4 B). Consistent
with a role in supporting the maintenance and identity of terminally fated CD8 T cells, we found a reduced accumulation of
KLRG1hiCX3CR1hi cells on day 25 of infection, with induced deletion of Brd4 and an enhanced abundance of multipotent
KLRG1loCX3CR1lo cells (Fig. 4 C). These data indicate that induced deletion of Brd4 in TE cells resulted in a loss of TE identity,
permitting transition to a KLRG1loCX3CR1lo memory-like phenotype; however, it is also possible that induced deletion of Brd4
results in the transition of EECs to KLRG1loCX3CR1lo cells.
We next assessed if delayed BET inhibition paralleled findings from delayed Brd4 deletion. On days 7–12 of LCMV infection, mice were treated with JQ1 or vehicle (Fig. 4 D). Consistent
with delayed deletion experiments, we found that BET inhibition resulted in a reduced frequency of TE cells (Fig. 4 D). Delayed treatment of JQ1 or tamoxifen also resulted in reduced GzB
expression and a greater frequency of TCF1hi cells (Fig. 4 E).
Finally, to clarify the lineage-specific role of BRD4 in maintaining TE identity, we sorted TE P14 cells, transferred the
congenically distinct TE cells into infection-matched recipient
mice, and subsequently treated recipients with JQ1 or vehicle
from day 8 through day 13 of infection. On day 14 of infection, we
evaluated the terminal phenotype of donor cells and found that
BET inhibition resulted in a rapid loss of KLRG1 and CX3CR1
expression compared with vehicle-treated mice (Fig. 4 F);
therefore, BRD4 is critical in enforcing a terminally differentiated state in TE cells.
Assessment of genome-wide occupancy of BRD4 revealed
robust binding in a multitude of lineage-specifying genes critical
to the identity of TE cells (Fig. 3 F). In other cell types, superenhancers (i.e., large clusters of conventional enhancers) are
known to control cell identity and can be regulated and
Journal of Experimental Medicine
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WT cells in peripheral blood (right). (B) Frequency of CD127, KLRG1, and CX3CR1 expressing tetramer+ cells on day 25 of infection from experimental setup in A.
(C) Ratio of Brd4fl/fl Ert2Cre/+ and control cells among all KLRG1hiCXCR1hi or KLRG1loCX3CR1lo tetramer+ CD8 T cell populations from A. (D) Naive P14 cells were
transferred to congenically distinct recipient mice and subsequently infected with LCMV. Recipient mice were treated with 50 mg/kg JQ1 or vehicle daily from
days 7–12 of infection. On day 13 of infection, the frequency of CD127- and KLRG1-expressing P14 cells was evaluated. (E) Frequency of TCF1- and GzBexpressing cells from experimental setup in A or D. (F) Sorted KLRG1hi P14 cells were transferred to infection-matched recipient mice that were subsequently
treated with daily 50 mg/kg JQ1 or vehicle (left). Frequency of KLRG1- and CX3CR1-expressing donor P14 cells on day 14 of infection. (G) ROSE algorithm
identified super-enhancers from ENCODE pipeline–processed H3K27ac ChIP-seq data from sorted TE cells (left; Yu et al., 2017). Gene set enrichment analysis
of genes nearest to TE super-enhancers compared between naive P14 cells and TE P14 cells (top right). Overlap of TE super-enhancers and TE BRD4 peaks
(bottom left), and gene set enrichment analysis of expression levels of nearest genes of BRD4 bound super-enhancers compared between tetramer+ Brd4−/− KO
TE and tetramer+ Brd4+/+ WT TE (bottom right). (H) Representative TE H3K27ac and BRD4 peaks at Bhlhe40, Klrg1, Gzmb, and Ccl5 loci with reproducible BRD4
peaks highlighted (gray) using the ENCODE ChIP-seq pipeline. Super-enhancer regions are demarcated with a blue line above the tracks. Graphs show mean ±
SEM of n = 10–15 mice pooled from three independent experiments (A–E) or n = 3 from one representative experiment (F). *, P < 0.05; ***, P < 0.005. NES,
normalized enrichment score; FDR, false discovery rate q value. Symbols represent an individual mouse (A–E).
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BRD4 regulates CD8 T cell differentiation in response
to tumors
Analogous to CD8 T cell subsets responding to infection, TILs
display a range of multipotent to terminally fated states within
the tumor microenvironment (Fig. S1 A; Kallies et al., 2020).
Given that BRD4 was central to the initiation and maintenance of
a terminally differentiated state during infection, we next assessed the role of BRD4 in supporting the differentiation of
terminally exhausted cells, characteristically marked by elevated Tim3 expression (Kallies et al., 2020; Miller et al., 2019;
Siddiqui et al., 2019), in a mouse model of melanoma. BRD4 was
required for the formation of terminally exhausted cells in an
antigen-specific CD8 T cell–intrinsic manner, evidenced by a
reduced frequency of Tim3hi TILs with Brd4 knockdown using
two distinct shRNAmirs (Fig. 5 A and Fig. S3 A). Consistent with
these results, we also found that daily in vivo treatment with JQ1
impaired the formation of Tim3hi tumor-specific TILs (Fig. 5 B).
Impaired generation of Tim3hi terminally fated TILs with Brd4
RNAi or JQ1 treatment emphasizes the central role of BRD4 in
coordinating the expression of genes critical to terminal CD8
T cell differentiation (as in Fig. 3 F and Fig. 4 H), and this fatespecifying activity is further underscored by a BRD4-occupied
super-enhancer region near Havcr2 encoding Tim3 (Fig. 5 C).
BET inhibition is an emerging treatment for diverse malignancies and is currently under investigation in >25 clinical trials
(Khandekar and Tiriveedhi, 2020); however, the focus of BET
inhibition in cancer therapies has been predominantly limited to
direct effects on malignant cells (Boi et al., 2015; Delmore et al.,
2011; Filippakopoulos et al., 2010; Khandekar and Tiriveedhi,
2020; Ott et al., 2012; Shi and Vakoc, 2014; Shu et al., 2016),
whereas the impact of in vivo BET inhibition on tumor immunity (Hogg et al., 2017; Mao et al., 2019; Zhu et al., 2016),
Milner et al.
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especially antitumor CD8 T cells, remains unclear. Given that
Brd4 knockdown and JQ1 treatment constrained CD8 T cell differentiation during infection and within tumors, we tested if we
could leverage these findings to modulate the efficacy of
promising immunotherapy approaches, such as adoptive cell
therapy and immune checkpoint blockade. We first tested how
JQ1 treatment impacted the efficacy of adoptive cell therapy in a
widely used and characteristically immunosuppressive B16
melanoma tumor model (Fig. 5 D; Chen et al., 2015; Juneja et al.,
2017; Kleffel et al., 2015). Upon adoptive transfer of tumorspecific T cells into immunocompetent mice bearing established melanoma tumors, we found that tumor growth was
delayed in vehicle-treated mice that received antitumor P14 cells
compared with mice that did not receive P14 T cells, as expected
(Fig. 5 D and Fig. S3 B); however, JQ1 treatment resulted in diminished efficacy of transferred tumor-specific P14 cells, ultimately yielding similar tumor growth rates to that of recipient
mice without P14 cells (Fig. 5 D and Fig. S3 B). Further evaluation
of the phenotype of adoptively transferred cells in JQ1-treated
mice or P14 cells deficient for BRD4 revealed failed production of
the essential cytolytic molecule GzB (Fig. 5 E), a direct target of
BRD4 (Fig. 4 H) characteristically expressed by terminally exhausted cells (Miller et al., 2019; Milner et al., 2020b; Siddiqui
et al., 2019). Furthermore, daily JQ1 treatment resulted in nearly
10-fold fewer P14 cells in the tumor microenvironment (Fig. S3
C). These findings highlight a scenario wherein BET inhibition
of terminal CD8 T cell differentiation may be problematic in an
adoptive cell therapy setting or perhaps in patients with a robust
antitumor CD8 T cell response. These results can be partially
explained by the finding that terminally exhausted cells produce
more GzB and exhibit superior antitumor cytotoxicity compared
with progenitor-exhausted cells (Miller et al., 2019), despite
their short-lived and terminal phenotype. It is important to note
that, although the phenotype of tumor-specific T cells in JQ1treated mice is similar to the phenotype detected with cellintrinsic Brd4 RNAi studies, BET inhibition may also indirectly
impact CD8 T cell responses through modulating the activity of
BET proteins in other cell types.
We speculated that the fairly aggressive regimen of daily
50 mg/kg JQ1 treatment in Fig. 5 D may excessively limit T cell
differentiation and effector capacity, and we next evaluated a
lower dose of 10 mg/kg JQ1. In vivo treatment with 10 mg/kg JQ1
resulted in a reduced frequency of Tim3hi tumor-specific cells
(Fig. 5 F) and a greater frequency of TCF1hi cells (Fig. S3 D)
compared with vehicle-treated mice, but not to the same extent
as that for 50 mg/kg JQ1. Given that terminally differentiated
CD8 T cells exhibit a fixed epigenetic state that limits longevity
and responsiveness to immunotherapies, such as immune
checkpoint blockade (Fig. S1 A; Pauken et al., 2016; Philip et al.,
2017; Siddiqui et al., 2019), we next tested if a 10-mg/kg JQ1
treatment course may allow for enhanced efficacy of α-PD-1
therapy through the blunting of terminal differentiation of P14
cells in tumors. Here, we used an MC38 colon carcinoma model
with known sensitivity to α-PD-1 therapy (Juneja et al., 2017).
Indeed, we found a 10-mg/kg JQ1 treatment regimen enhanced
the efficacy of α-PD-1, wherein only ∼17% of vehicle-treated
mice responded to α-PD-1 therapy compared with nearly 50%
Journal of Experimental Medicine
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interpreted by BRD4 (Dey et al., 2019; Lee et al., 2017; Lovén
et al., 2013); however, the regulation of super-enhancer activity in CD8 T cells remains unexplored. We next sought to understand if BRD4 occupied and regulated super-enhancer
regions, potentially explaining the critical role of BRD4 in enforcing TE identity. Similar to previous reports (He et al., 2016),
we called 554 TE super-enhancers through the ROSE algorithm
using H3K27ac ChIP-seq data of sorted TE cells (Yu et al., 2017),
which was processed by the ENCODE ChIP-seq pipeline
(Fig. 4 G). Genes nearest to identified super-enhancer regions
were characteristically upregulated in TE cells compared with
naive cells, supporting the biological relevance and overall robustness of the super-enhancer peak calling (Fig. 4 G, top). Next,
we evaluated the extent to which BRD4 occupied these identified
super-enhancer regions and found that, remarkably, 549 of 554
(>99%) super-enhancers overlapped with BRD4 binding
(Fig. 4 G, bottom). We detected impaired expression of genes
associated with BRD4-occupied super-enhancers in BRD4deficient TE cells (Fig. 4 G, bottom right). Notable superenhancer regions occupied by BRD4 with failed upregulation
of the nearest genes in Brd4−/− TE cells included TE-associated
genes Zeb2, Gzma, Kdm6b, as well as Bhlhe40, Gzmb, Klrg1, and
Ccl5, highlighted in Fig. 4 H, implicating BRD4 as a robust regulator of the TE gene expression program.
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of mice responding to α-PD-1 in combination with 10-mg/kg JQ1
treatment (Fig. 5 G). These data highlight that resolving the roles
BET proteins and their degree of activity in antitumor CD8
T cells may yield insight into enhancing BET therapy efficacy
and synergy, which is particularly relevant given that early
findings from clinical studies of BET inhibitors as a cancer
monotherapy leave room for improvement (Khandekar and
Tiriveedhi, 2020).
This investigation provides insight into how complex chromatin dynamics accompanying CD8 T cell differentiation are
interpreted and conveyed during infection. We established that
Milner et al.
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BRD4 binds to gene bodies, traditional enhancers, and superenhancers to regulate the expression of genes critical to
effector differentiation and identity, including pro-effector
transcription factors (Id2, Bhlhe40, Zeb2, and Runx1), effector
molecules (Gzma, Gzmb, and Fasl), and canonical TE-surface
molecules or mediators of cell trafficking (Klrg1, Cx3cr1, Itgam,
Ccr5, and Ly6c2). Brd4 expression is relatively uniform among
diverse CD8 T cell populations, highlighting the utility of our
RNAi screening strategy and indicating that the fate-specifying
activity of BRD4 is likely dictated by the cis regulatory landscape
as CD8 T cells gain nearly twofold more de novo enhancer
Journal of Experimental Medicine
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Figure 5. BRD4 regulates CD8 T cell differentiation during cancer. (A) Experimental schematic (left) wherein congenically distinct P14 cells were
transduced with Brd4 shRNA–encoding or control shRNA–encoding retroviruses. Transduced cells were transferred into mice bearing established B16-GP33-41
tumors as in Fig. S3 A. Representative flow cytometry plots (left) and quantification (right) of the frequency of shBrd4 or shCtrl cells on days 11 or 12 after
transplant. (B) P14 cells were transferred into recipient mice bearing established B16-GP33-41 tumors, and recipient mice were treated daily with 50 mg/kg JQ1
or vehicle daily. Frequency of PD-1hiTim3hi P14 cells on days 12 and 18 after transplant. (C) Representative TE H3K27ac and BRD4 peaks near Havcr2 (encoding
Tim3). A super-enhancer region is demarcated with a blue line above the tracks. Reproducible BRD4 peaks are highlighted (gray) using the ENCODE ChIP-seq
pipeline. (D) P14 cells were adoptively transferred to B16-GP33-41 tumor-bearing mice subsequently treated with JQ1 (50 mg/kg) or vehicle daily for the first
week after adoptive transfer and then every other day thereafter. Tumor volume was assessed and responders were defined as mice with a nonulcerated
tumor <500 mm3 on day 20 after transplant. (E) Frequency of GzB-expressing P14 cells from experimental setup in A or B. (F) P14 cells were adoptively
transferred to B16-GP33-41 tumor-bearing mice that were subsequently treated with 50 mg/kg JQ1, 10 mg/ml JQ1, or vehicle daily and the frequency of PD1hiTim3hi cells was evaluated. (G) MC38-GP33-41 tumor-bearing mice were treated with 0.2 mg α-PD-1 every 2 d beginning on day 8 after transplant and
10 mg/kg JQ1 daily beginning on day 11 after transplant. Tumor volume was assessed and responders were defined as mice with a nonulcerated tumor
<200 mm3 on day 27 after transplant. Graphs show mean ± SEM of n = 6–17 pooled from two to four independent studies (A, B, and D–G) or n = 4 from one
representative of two independent studies (E, left). *, P < 0.05; ***, P < 0.005. Symbols represent an individual mouse (A, B, E, and F).
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Materials and methods
Mice
All mice were bred and housed in specific pathogen–free conditions in accordance with the Institutional Animal Care and Use
Guidelines of the University of California San Diego or the National Institute of Child Health and Human Development. P14
mice (with transgenic expression of H-2Db–restricted TCR specific for LCMV glycoprotein GP33-41), Brd4fl/fl Ert2Cre/+ (Dey et al.,
2019), and CD45.1 and CD45.2 congenic mice were bred inhouse. Male and female mice were used with sex-matched
T cell donors and recipients or female cells were transferred
into male recipients.
T cell transfers, bone marrow chimeras, infections,
and treatments
For BET inhibition studies, naive P14 cells (5 × 104) were
transferred into congenically distinct recipient mice subsequently infected with 2 × 105 PFU of LCMV by i.p. injection. The
following BET inhibitors were used in this study: JQ1 (prepared
by the laboratory of Jun Qi), OTX-015 (MedChemExpress), and
MS402 (prepared by the laboratory of Ming-Ming Zhou). A concentrated stock of JQ1 in DMSO was prepared at 50 mg/ml and diluted 1:10 in 10% cyclodextrin, and mice received 50 mg/kg or
10 mg/kg via i.p. injection as indicated. A concentrated stock of OTX015 in DMSO was prepared at 50 mg/ml and diluted in sunflower oil,
and 50 mg/kg was administered via oral gavage. A concentrated
stock of MS402 in DMSO was prepared at 20 mg/ml and diluted in
10% cyclodextrin, and 40 mg/kg was administered i.p. Administered
vehicle control for all inhibitors was DMSO in 10% cyclodextrin (i.p
injections) or sunflower oil (oral gavage treatments).
Mixed bone marrow chimera mice were established by
transferring a 1:1 mix of Brd4fl/flErt2Cre/+ bone marrow cells with
congenically distinct WT Brd4+/+ bone marrow cells into irradiated
congenically distinct recipient mice. After reconstitution (∼12 wk
after transfer), chimeric mice were then infected with LCMV. For
ER-Cre–mediated deletion of floxed alleles, 2 mg tamoxifen (Cayman Chemical Company) was administered daily by i.p. injection
for 3–5 consecutive days at various time points after infection.
Milner et al.
BRD4 regulates CD8 T cell differentiation

In vivo RNAi screen
The pooled in vivo shRNAmir screen was performed similarly as
previously described (Milner et al., 2017). Briefly, P14 cells were
activated in 96-well plates, individually transduced with 215
distinct shRNAmir encoding retroviruses, pooled, and 5 × 105
total P14 cells were transferred into 15–18 recipient mice subsequently infected with LCMV. Twelve days after infection,
CD62Lhi and CD62Llo splenic P14 cells were sorted and genomic
DNA was harvested. Proviral passenger strand shRNAmir sequences were PCR amplified, and a minimum of 2.5 million
reads per sample were generated and retained after filtering
low-quality reads. shRNAmir representation in CD62Llo cells
relative to CD62Lhi cells was calculated by normalizing the total
number of reads in each of the samples, and then the number of
reads for each shRNAmir was scaled proportionally. Subsequently, the normalized number of reads in the CD62Llo cells for
a given shRNAmir was divided by the normalized number of
reads for the same shRNAmir in the CD62Lhi cell sample and
then log2 transformed. Mean and SD of the ratios of 25 negative
control shRNAmir constructs (targeting Cd19, Cd4, Cd14, Ms4a1,
Cd22, Hes1, Klf12, Mafb, Plagl1, Pou2af1, and Smarca1) were used to
calculate the Z-score for each shRNAmir. The in vivo screen was
repeated three times and the Z-score of each construct from each
individual screen was averaged. All constructs were screened
two to three times (except for 13 constructs, which are marked
by an asterisk in Table S1) as certain constructs were added after
the first screen or were not detectable in one of the replicate
experiments.
In vivo Brd2 and Brd4 RNAi during LCMV infection
For in vivo Brd2 and Brd4 RNAi experiments, two distinct
shRNAmir clones for each gene were used in our previously
described pLMPd-Amt vector (Chen et al., 2014; Wang et al.,
2018), and retroviral supernatant was produced as described
previously (Milner et al., 2017). For transfections, Plat-E cells
were seeded in 10-cm dishes at a density of 2.5 × 105 cells/plate
1 d before transfection in serum-free media. Transfections were
performed with 100 µg plasmid DNA from each pLMPd-Amt
clone and 50 µg pCL-Eco with TransIT-LT1 (Mirus). Retroviral
supernatant was harvested 48 h and 72 h after transfection. For
transductions, negatively enriched naive CD8 T cells from spleen
and lymph nodes were activated in 6-well plates coated with
100 µg/ml goat anti-hamster IgG (H+L; Thermo Fisher Scientific), 1 µg/ml anti-CD3 (145-2C11; eBioscience), and 1 µg/ml antiCD28 (37.51; eBioscience). T cell culture media was removed 18 h
after activation and replaced with retroviral supernatant supplemented with 50 µM β-mercaptoethanol (Gibco) and 8 µg/ml
polybrene (Millipore) followed by a 1 h spinfection centrifugation at 2,000 rpm and 37°C. One day after transduction, congenically distinct ametrine+ T cells were mixed 1:1 and 5 × 105
total cells were transferred into recipient mice subsequently
infected with LCMV.
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regions during their transition from a naive cell to a TE cell state
compared with an MP state (Yu et al., 2017). BRD4 activity may
also be regulated by post-translational modifications (Shu et al.,
2016; Wu et al., 2013) and/or interactions with other regulatory
molecules, such as mediators of transcription elongation (Chen
et al., 2014; Jang et al., 2005; Yang et al., 2005). BRD4 is widely
classified as a chromatin reader, but has diverse functions
ranging from kinase activity (Devaiah et al., 2012) to binding
nonhistone acetylated molecules, such as p65 (Huang et al.,
2009). While it is possible that BRD4 controls T cell fate during infection and cancer through a range of actions, assessment
of genome-wide binding patterns indicates that a primary
function of BRD4 in CD8 T cells is regulating expression of key
genes through supporting transcription of gene bodies directly
and promoting activity of super-enhancers. Taken together, we
identify BRD4 as a critical regulator of CD8 T cell differentiation
and function during infection and cancer.

Tumor models
Tumors were established by transplanting 5 × 105 B16-GP33-41
cells or 2.5–5 × 105 MC38-GP33-41 cells subcutaneously. Cell lines
was treated for mycoplasma contamination and authenticated in
Journal of Experimental Medicine
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Antibodies, intracellular staining, flow cytometry, and cell sorting
Single-cell suspensions were prepared from spleen or lymph
node by mechanical disruption, and intestinal tissue and tumor
were processed as described previously (Milner et al., 2017).
RBCs were lysed with ACK buffer (140 mM NH4Cl and 17 mM
Tris-base, pH 7.4). The following antibodies were used for
surface staining (all from eBioscience unless otherwise specified): CD8 (53–6.7), CD27 (LG-7F9), CD43 (eBioR2.60), CD44
(IM7), CD45.1 (A20-1.7), CD45.2 (104), CD69 (H1.2F3; BioLegend),
CD103 (2E7), Tim3 (RMT3-23), CD127 (A7R34), CD62L (MEL-14),
KLRG1 (2F1), PD-1 (J43), and CX3CR1 (SA011F11; BioLegend); or
intracellular staining: GzB (GB12; Invitrogen), Eomes (Dan11mag), TCF1 (C63D9; Cell Signaling Technology), T-bet (4B10),
and Ki-67 (SolA15). The H-2Db-GP33-41 tetramer was obtained
from the National Institutes of Health Tetramer Core. Intracellular staining was performed using the Foxp3 Transcription
Factor Staining Buffer Set (eBioscience). CellTrace Violet
(Ebioscience) and BrdU (BD PharMingen) were used per manufacturer instructions where 2 mg BrdU was administered i.p.
2 h before tissue harvesting. For flow cytometry analysis, all data
were acquired on a BD LSRFortessa X-20 or a BD LSRFortessa.
Cell sorting was performed on BD FACSAria or BD FACSAria
Fusion instruments.
Quantitative PCR and RNA sequencing
For validation of Brd2 and Brd4 knockdown with shRNAmir
constructs, enriched CD8+ T cells were activated, transduced,
and expanded for 4–6 d in 100 mg/ml IL-2. Ametrine+ cells (Brd2
shRNAmir, Brd4 shRNAmir, or control Cd19 shRNAmir) were
sorted directly into TRIzol (Life Technologies) and RNA was
extracted per manufacturer specifications. cDNA was then
synthesized using Superscript II (Life Technologies) and quantitative PCR was performed using the Stratagene Brilliant II
Syber Green master mix (Agilent Technologies). Brd2 and Brd4
expression levels were normalized to the housekeeping genes
Hprt1 or Gapdh. The following primers were used for quantitative
PCR: Brd2 forward: 59-GCTGAGCGGCGGCGGTTCCC-39, and Brd2
reverse: 59-GTAAAG CTGGTACAGAAGCC-39; Brd4 forward: 59TTCAGCACCTCACTTCGA CC-39, and Brd4 reverse: 59-CTGGTG
TTTTTGGCTCCTGC-39; Hprt forward: 59-GGCCAGACTTTGTTG
Milner et al.
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GATTT-39, and Hprt reverse: 59-CAACTTGCGCTCATCTTAGG-39;
and Gapdh forward: 59-CCAGTATGACTC CACTCACG-39, and
Gapdh reverse: 59-GACTCCACGACATACTCAGC-39.
For RNA sequencing studies, 103 P14 cells were sorted on day
5 of infection or tetramer+ cells were sorted on day 8 of infection. RNA sequencing was performed in duplicate or triplicate
wherein day 5 JQ1/vehicle or shBrd4/shCtrl P14 replicates or
day 8 tetramer+ replicates were sorted from cells pooled from
two mice (i.e., each replicate was composed of cells from two
separate mice). For all samples, polyA+ RNA was isolated and
RNA sequencing library preparation and RNA sequencing
analysis were performed as described (https://www.immgen.
org/Protocols/11Cells.pdf). Heatmaps were generated using
Morpheus (https://software.broadinstitute.org/morpheus).
Gene set enrichment analysis was performed with gene set
enrichment analysis v4.0.3: Number of permutations = 1,000,
permutation type = gene_set, enrichment statistic = weighted,
metric for ranking genes = Signal2Noise. MP, TE, and EEC
signature gene sets were generated by identifying genes differentially expressed between each subset in WT tetramer+
cells on day 8 of infection (1.5-fold change, expression
threshold ≥ 10).
BRD4 ChIP-seq
For ChIP-seq studies, 105 naive P14 cells were transferred to
recipient mice subsequently infected i.p. with 2 × 105 PFU of the
Armstrong strain of LCMV 1 d after cell transfer. Negatively
enriched splenocytes were sorted for TE cells (KLRG1+CD127−)
on day 8 after infection. Duplicate samples were prepared for
subsequent ChIP-seq analyses, wherein each replicate consisted of 1.5 × 107 TE cells pooled from five mice. Cells were
then fixed by adding 1/10 volume of freshly prepared 37%
formaldehyde (#F-8775; Sigma-Aldrich) for 15 min. Fixation
was then stopped by adding 1/20 volume of 2.5 M Glycine for
5 min. Cells were washed with chilled 0.5% Igepal/PBS and
1 mM PMSF, and then cell pellets were flash frozen and
shipped to Active Motif for anti-BRD4 (Bethyl A301-985A100)
ChIP-seq. For BRD4 ChIP reactions, 25 μg chromatin and 6 μl
antibody were used. Fastq files for H3K27ac ChIP-seq in TE
OT-I cells were downloaded from the Gene Expression Omnibus (accession no. GSE89036). The Fastq files for BRD4 from
Active Motif and for H3K27ac ChIP-seq were analyzed
through the Chip-seq pipeline from Encode (https://www.
encodeproject.org/pipelines/), and the reproducible peak
sets along with the bigwig tracks of fold change over background were used. The ROSE algorithm (Lovén et al., 2013;
Whyte et al., 2013) was used to identify super-enhancers from
the H3K27ac peak set. Homer was used to annotate the peak
sets and compare BRD4 binding and super-enhancer locations
(http://homer.ucsd.edu/homer/).
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in vitro killing assays. P14 cells were in vitro expanded in
IL-2 (100 mg/ml) for 2–4 d, after which 1–2 × 106 cells (or 4 ×
106 cells; Fig. 5 D) were transferred into congenically distinct
tumor-bearing mice 7–8 d after transplant. Mice were treated with JQ1 or vehicle as described above. Brd4 RNAi experiments in tumors were performed as described above,
except transduced cells were cultured for 2–3 d after transduction before mixed transfer. For immune checkpoint
blockade studies, 0.2 mg of α-PD-1 or isotype control were
administered i.p. every other day beginning on day 7/8 after
transplant. Tumors were monitored every 2–3 d, and mice
with ulcerated tumors or tumors exceeding 1,500 mm3 were
euthanized, in accordance with the Institutional Animal Care
and Use Guidelines of the University of California San Diego.
TILs were isolated as previously described (Milner et al.,
2017).

Statistics
Statistical analysis was performed using GraphPad Prism software. Two-tailed paired or unpaired t test was used for comparisons between two groups. P values of <0.05 were considered
significant. Log-rank (Mantel-Cox) test was used to compare
survival curves.
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Online supplemental material
Fig. S1 provides supporting information on the efficacy of Brd4
RNAi and inducible floxed models, as well as further phenotyping of Brd4-deficient CD8 T cells. Fig. S2 illustrates expression patterns of BET proteins in CD8 T cell populations during
LCMV infection and provides information on the phenotype of
Brd2-deficient CD8 T cells. Fig. S3 lists details on the phenotype
of Brd4-deficient T cells in mouse melanoma tumors. Table S1
shows summary Z-scores from the in vivo RNAi screening
approach.
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Figure S1. BRD4 regulates CD8 T cell differentiation during infection. (A) Model of effector and memory T cell populations during infection and their
corresponding characteristics (top). Spectrum of CD8 T cell states during infection and cancer (bottom). (B) Gene expression analysis of Brd4 in sorted CD8
T cells transduced with shBrd4- or shCtrl-encoding retroviruses after in vitro culturing for 4–5 d. (C) Congenically distinct P14 cells were transduced with Brd4
shRNA–encoding or control shRNA–encoding retroviruses and transferred into recipient mice that were subsequently infected with LCMV. The frequency of
CD103- and CD69-expressing P14 cells in the epithelium of the small intestine on day 7 of infection was evaluated. (D) RNA sequencing expression levels of the
floxed Brd4 region based on the experimental schematic in Fig. 3 A. (E) Bone marrow chimera mice were generated by adoptive transfer of 1:1 mixed bone
marrow cells from CD45.1 Brd4+/+ control mice (Ctrl) and CD45.2 Brd4fl/flErt2Cre/+ mice (inducible Brd4 [iBrd4]) into irradiated mice (left). Reconstituted mice
were infected with LCMV and treated with tamoxifen on days 1–5 of infection to induce deletion of Brd4. Representative flow cytometry plots (right) and
quantification (bottom left) of the ratio of Brd4fl/flErt2Cre/+ and control cells before infection and 8 d after infection. (F) Frequency of CD127- and KLRG1expressing tetramer+ cells from D. (G) Naive P14 CD8 T cells were transferred into congenically distinct recipient mice that were subsequently infected with
LCMV. Infected mice were treated daily with 50 mg/kg JQ1 or vehicle (left). Frequency of CD103- and CD69-expressing P14 cells in the epithelium of the small
intestine on day 7 of infection (right). Graphs show mean ± SEM of n = 5–8 mice pooled from two independent experiments (C–E); n = 4 from one representative of two independent experiments (F); or data pooled from three independent experiments (B). *, P < 0.05; ***, P < 0.005. Symbols represent an
individual mouse (C–F). IEL, intraepithelial lymphocyte.
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Figure S2. Impact of Brd2 knockdown on CD8 T cell differentiation during infection. (A) Global relative expression of BET family members among naive,
effector (D7), and memory populations (D35) from Milner et al. (2017). (B) Gene expression analysis of Brd2 in sorted CD8 T cells transduced with shBrd2- or
shCtrl-encoding retroviruses. (C) Congenically distinct P14 cells were transduced with Brd2 shRNA–encoding or control shRNA–encoding retroviruses.
Transduced cells were transferred into recipient mice that were subsequently infected with LCMV, and the phenotype of donor cells was evaluated on day 7 of
infection. *, P < 0.05; ***, P < 0.005. IEL, intraepithelial lymphocyte.

Figure S3. JQ1 treatment impairs adoptive cell therapy efficacy in an immunocompetent mouse model. (A) Model for Fig 5 A, wherein congenically
distinct P14 cells were transduced with two distinct Brd4 shRNA–encoding or control shRNA–encoding retroviruses. Transduced cells were then mixed 1:1 and
transferred into mice bearing established B16-GP33-41 tumors. (B) Tumor growth and mortality from experiment in Fig. 5 D. (C) P14 cells were enumerated in
the tumor, tumor draining lymph node (dLN), and spleen 8–12 d after adoptive transfer with daily treatment of 50 mg/kg JQ1 or vehicle. (D) Frequency of
TCF1hiGzBlo P14 cells after daily in vivo treatment of 50 mg/kg JQ1, 10 mg/kg JQ1, or vehicle in tumor-bearing mice. (E) Model of CD8 T cell states during
infection and cancer (left) and summary of the role of BRD4 and JQ1 treatment in the regulation of CD8 T cell differentiation (right). Graphs show mean ± SEM
of n = 11–16 mice pooled from two independent experiments (B); n = 11–12 mice pooled from three independent experiments (D); or n = 22–24 pooled from six
independent experiments (C). *, P < 0.05; **, P < 0.01; ***, P < 0.005. Symbols represent an individual mouse (C and D).

Table S1 is provided online and shows summary Z-scores from in vivo RNAi screening approach.
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